| Literature DB >> 27030389 |
Konstantinos Georgiou1, Longyun Chen2, Mattias Berglund3, Weicheng Ren1, Noel F C C de Miranda4, Susana Lisboa5, Marco Fangazio6, Shida Zhu7, Yong Hou7, Kui Wu7, Wenfeng Fang8, Xianhuo Wang9, Bin Meng9, Li Zhang8, Yixin Zeng8, Govind Bhagat10, Magnus Nordenskjöld11, Christer Sundström12, Gunilla Enblad12, Riccardo Dalla-Favera6, Huilai Zhang9, Manuel R Teixeira5, Laura Pasqualucci6, Roujun Peng8, Qiang Pan-Hammarström1.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of B-cell lymphoma. Deregulation of proto-oncogene expression after a translocation, most notably to the immunoglobulin heavy-chain locus (IGH), is one of the hallmarks of DLBCL. Using whole-genome sequencing analysis, we have identified the PD-L1/PD-L2 locus as a recurrent translocation partner for IGH in DLBCL. PIM1 and TP63 were also identified as novel translocation partners for PD-L1/PD-L2 Fluorescence in situ hybridization was furthermore used to rapidly screen an expanded DLBCL cohort. Collectively, a subset of samples was found to be affected by gains (12%), amplifications (3%), and translocations (4%) of the PD-L1/PD-L2 locus. RNA sequencing data coupled with immunohistochemistry revealed that these cytogenetic alterations correlated with increased expression of PD-L1 but not of PD-L2 Moreover, cytogenetic alterations affecting the PD-L1/PD-L2 locus were more frequently observed in the non-germinal center B cell-like (non-GCB) subtype of DLBCL. These findings demonstrate the genetic basis of PD-L1 overexpression in DLBCL and suggest that treatments targeting the PD-1-PD-L1/PD-L2 axis might benefit DLBCL patients, especially those belonging to the more aggressive non-GCB subtype.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27030389 DOI: 10.1182/blood-2015-12-686550
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113